US health regulators have given final approval to Novavax's COVID vaccine after an unusual delay and have placed new ...

The FDA has approved Novavax’s protein-based COVID-19 vaccine, giving some Americans another option besides messenger RNA vaccines to prevent SARS-CoV-2 infection.

The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax's COVID-19 vaccine, but only for certain ...

Members of the World Health Organization voted emphatically in favour of a potentially groundbreaking global treaty on ...

The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition. The approval is based on ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

Novavax Inc. jumped as US regulators fully approved its Covid vaccine, easing investors’ concerns after the clearance was ...

Novavax had expected full approval for broader use by April 1, after the FDA reviewed data from a 30,000-person clinical ...

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Health agencies working under Robert F. Kennedy Jr. are making changes to the nation's decades-old system for approving and ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.